Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Onquality Pharmaceuticals China Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners and 2 distinct art units. BAUER, BRIANNA LEE is the busiest examiner for the portfolio, currently handling 1 pending office action.
With 3 distinct examiners each managing 1 of the 3 pending office actions, the prosecution workload is distributed across the personnel involved. The presence of 2 distinct art units indicates that the company's pharmaceutical filings are being reviewed by two different specialized groups. Resolving the 3 pending office actions will require the applicant to navigate 3 different examiner perspectives and the specific technical requirements of 2 distinct art units. This variety in examiners and art units suggests that each of the 3 pending actions may follow a unique prosecution path based on individual examiner feedback. The applicant must engage with 3 distinct examiners to successfully conclude the active matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 100.0% | +0.0% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| LEESER, ERICH A | 1 | 81.8% | +13.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259532 | REAGENT AND METHOD FOR TREATING SKIN DISEASES OR CONDITIONS ASSOCIATED WITH ANTI-TUMOR AGENT | LEESER, ERICH A | 9d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840432 | COMPOUND AND USE THEREOF | BAUER, BRIANNA LEE | — |
| 18259716 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | CHONG, YONG SOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259532 | REAGENT AND METHOD FOR TREATING SKIN DISEASES OR CONDITIONS ASSOCIATED WITH ANTI-TUMOR AGENT | LEESER, ERICH A | 9d overdue |
| 18259716 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840432 | COMPOUND AND USE THEREOF | BAUER, BRIANNA LEE | — | §102§103§112 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18259716 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | CHONG, YONG SOO | 1623 | §102§112Other | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18259532 | REAGENT AND METHOD FOR TREATING SKIN DISEASES OR CONDITIONS ASSOCIATED WITH ANTI-TUMOR AGENT | LEESER, ERICH A | 1622 | §112Other | Non-Final OA | 9d overdue | Pending | Jun 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial